To the Editor,
Response to Q1: Although the three studies mentioned are very good, we had to exclude them because they did not meet the inclusion criteria of our research. For example, the study by Betts et al. had a 24-week open-label phase design [7] . The study by Zhou et al. did not report data on efficacy and adverse events [8] . The study by Kwan et al. included patients with generalized epilepsies, and we were unable to extract the adverse events' data relating to patients with focal seizures from the data as presented [9] . In addition, this study did not report data for different BRV doses [9] . Please refer to our inclusion criteria and note that such inclusion criteria have to be applied very strictly in a metaanalysis.
Response to Q2: Please note that all important and available data of design and baseline were shown in Tables 1 and 2 . Only the duration of titration in the LEV groups was longer than that in BRV groups. However, there is no evidence to suggest that a longer duration of titration could increase the efficacy of LEV. Therefore, it is not likely that the efficacy of LEV was overstated in our analysis.
Response to Q3: There may well be heterogeneity between trial populations given that only a modest number of baseline characteristics were available for comparison. However, the total LEV group included 1765 patients and the BRV group 1919 patients. These large sample sizes could balance out the heterogeneity from small populations of individual studies and the potential confounding effects associated with baseline heterogeneity.
Response to Q4: Yes, the trials included in our analysis were published during 2000 to 2015. To include all eligible studies is a key feature and particular strength of systemic reviews or metaanalyses. We cannot assess the heterogeneity with regards to prior treatment attempts and comorbidity profile because relevant data was not available to us. However, prior treatment attempts and comorbidity profiles should not affect our results because the different studies used similar inclusion criteria. After performing a meta-analysis using random-effects model and OpenMeta (www. cebm.brown.edu), we found that the overall 50% seizure frequency improvement rate to placebo was 16% in the LEV studies (95% confidence interval = 9-22%, P < 0.01) and 18% in the BRV studies (95% confidence interval = 14-21%, P < 0.01). Therefore, there is no ''large difference'' in the placebo response rates between the LEV and BRV groups.
Response to Q5: Unmeasured confounding factors exist in almost all trials, not only in epilepsy studies. Does this mean that all of these trials should be discounted? Even if the unmeasured confounding factors remained between LEV and BRV groups, the large sample sizes of our meta-analysis are sufficient to counterbalance their influence on our results.
Response to Q6: Actually, even if we remove the data of nontherapeutic doses, there is still no significant difference in the 50% responder rate between a BRV dose of 50 mg/day and a LEV dose of 1000 mg/day. This modification of our analyses would therefore not affect our conclusions. Response to Q7: We do not agree with this point raised by Borghs and his colleagues. Although only one of the presented confidence intervals reaches significance, overall risk ratios of the 50% responder rate exceed 1 with a lower confidence limit of 0.98. We believe that our data is likely to reflect differences in the clinical profile of LEV and BRV. As neurologists, we would like the efficacy and safety of BRV to be greater than that of LEV. However, we cannot be certain that BRV is superior to LEV on the basis of the LEV, levetiracetam; ITT, intent-to-treat; SD, standard deviation; BSF, baseline seizure frequency; RDBPCT, randomized, double-blind, placebo-controlled trial; AEDs, antiepileptic drugs. evidence available to far. So we re-assert our conclusion that future RCTs with sufficiently large numbers of participants are needed to confirm or refute our findings. There are previous examples of the findings of indirect metaanalysis being proven by RCTs: an indirect comparison study suggested that pregabalin and LEV were associated with a similar proportion of patients experiencing an at least 50% improvement in seizure frequency (odds ratio = 1.15, 95% confidence interval = 0.47-2.83, P = 0.33) [3] . A subsequent RCT comparing a pregabalin dose of 450 mg/day and a LEV dose of 2000 mg/day reached a similar conclusion (odds ratio of 50% seizure reduction = 1.16, 95% confidence interval = 0.80-1.67, P = 0.44) [10] . Therefore, we will continue to believe in our results until they are proven wrong by a fully powered direct comparison of LEV and BRV.
